Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Saudi Pharm J
; 30(8): 1079-1087, 2022 Aug.
Article
en En
| MEDLINE
| ID: mdl-36164567
6MWT, 6-minute walking test; 95% CIs, 95% confidence intervals; BD, baseline data; CD, change data; E/e', early diastolic mitral inflow to annular velocities; FD, final data; HFpEF, heart failure with preserved ejection fraction; Heart failure with preserved ejection fraction; KCCQ, Kansas City cardiomyopathy questionnaire; LAVI, left atrial volume index; LV, left ventricular; MeSH, Medical Subject Heading; Meta-analysis; NT-proBNP, N-terminal fragment of the precursor to brain-type natriuretic peptide; PAP, pulmonary arterial pressure; PASP, pulmonary artery systolic pressure; PDE, phosphodiesterase; PH, pulmonary hypertension; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PVR, pulmonary vascular resistance; Phosphodiesterase inhibitor; QOL, quality of life; RCTs, randomized controlled trials; RR, risk ratio; RV, right ventricular; Right ventricular dysfunction; SMD, standardized mean difference; TAPSE, tricuspid annular plane systolic excursion; VO2, oxygen uptake; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
Saudi Pharm J
Año:
2022
Tipo del documento:
Article
País de afiliación:
China